MBOT — Microbot Medical Inc
NASDAQ · Health Care · Health Care
- Latest Close
- $2.15
- 30-Day Move
- -10.4%
- Market Cap
- $161M
- Shares Outstanding
- 67,160,000
- P/B Ratio
- 1.73
- ROE
- -17.0%
Analyst consensus: Buy · 9 analysts
Microbot Medical Inc
A read-only Alphactor snapshot forMicrobot Medical Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$2.15
30-Day Move
-10.4%
Market Cap
$161M
Shares Outstanding
67,160,000
P/B Ratio
1.73
ROE
-17.0%
$2.15
-10.4%last 90 delayed daily bars
90D High
$2.85
90D Low
$1.60
Avg Volume
1,886,566
Gross margin is running at 75.2%, which gives a quick read on operating quality before you open the full model.
Net margin is -3886.6%, useful for comparing MBOT against peers in Health Care.
MBOT is down 10.4% over the last 30 trading days shown on this page.
Latest operating income is $-4M, which helps anchor the headline ratios with an actual earnings figure.
Latest Close
$2.15
30-Day Move
-10.4%
Market Cap
$161M
Shares Outstanding
67,160,000
P/B Ratio
1.73
ROE
-17.0%
ROA
-16.1%
Gross Margin
75.2%
Operating Margin
-4163.9%
Net Margin
-3886.6%
Debt / Equity
0
Current Ratio
23.33
Latest Revenue
$0
Revenue
$0
Gross Profit
--
Operating Income
$-4M
Net Income
$-3M
Gross Margin
7523.0%
Net Margin
-388660.0%
Current Ratio
23.33
Debt / Equity
0.00
Altman Z
22.98
Safe
Piotroski
4
Moderate (4-6)
Cash Conversion
0.99x
Rule of 40
--
Insufficient data
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-13M | $-13M | $-12M |
| 2023-12-31 | $0 | $-10M | $-11M | $-9M |
| 2024-12-31 | $0 | $-12M | $-11M | $-9M |
| 2025-12-31 | $0 | $-15M | $-13M | $-13M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Vanguard Group
Filed 2025-11-07
$7M
+14.3%
Geode Capital Management
Filed 2026-02-09
$2M
+54.4%
Citadel Advisors
Filed 2025-11-14
$740,235
--
Qube Research & Technologies
Filed 2026-02-17
$263,392
--
Northern Trust
Filed 2025-11-14
$244,323
+12.7%
4.11
Consensus
Buy—
—
—
9
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.